Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients
BACKGROUND: Graft-versus-host disease (GVHD) is a main complication following allogeneic hematopoietic stem cell transplantation and is a leading cause of non-relapse-related death. Unsatisfactory response to standard first-line therapy with glucocorticoids is a predictor of a poor prognosis in pati...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646859/ https://www.ncbi.nlm.nih.gov/pubmed/34880598 http://dx.doi.org/10.2147/DDDT.S338752 |
_version_ | 1784610519973363712 |
---|---|
author | Wei, Cong Zhang, Xiaoting Liang, Dan Yang, Jilong Du, Jingwen Yue, Chunyan Deng, Lan |
author_facet | Wei, Cong Zhang, Xiaoting Liang, Dan Yang, Jilong Du, Jingwen Yue, Chunyan Deng, Lan |
author_sort | Wei, Cong |
collection | PubMed |
description | BACKGROUND: Graft-versus-host disease (GVHD) is a main complication following allogeneic hematopoietic stem cell transplantation and is a leading cause of non-relapse-related death. Unsatisfactory response to standard first-line therapy with glucocorticoids is a predictor of a poor prognosis in patients with GVHD. Ruxolitinib is a selective Janus kinases 1/2 inhibitor which has been shown to control acute (a) and chronic (c) GVHD while maintaining graft-versus-tumor effects. OBJECTIVE: This study aims to evaluate the efficacy and safety of ruxolitinib in the treatment of steroid-refractory GVHD (SR-GVHD) in a population of Chinese patients. METHODS: We report the results of 55 patients, including 23 patients with aGVHD and 32 patients with cGVHD, who were treated with ruxolitinib as salvage therapy between August, 2017 and December, 2020. RESULTS: In patients with aGVHD, the overall response rate (ORR) was 86.9%, and the 1-year overall survival (OS) was 82.6% (95% CI, 67.1–98.1%). The 1-year OS was significantly improved in responders than in non-responders (90.0% vs 33.3%, P=0.004). In patients with cGVHD, the ORR was 78.1%, and the 1-year OS was 81.3% (95% CI, 67.8–94.8%). There was no significant difference in the 1-year OS between responders and non-responders (84.0% vs 71.4%, P=0.327). Cytopenia, cytomegalovirus-reactivation and infections were common adverse events, particularly in patients with aGVHD. CONCLUSION: Our real-world data from Chinese patients further confirm that ruxolitinib is a safe and effective treatment for SR-GVHD. |
format | Online Article Text |
id | pubmed-8646859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-86468592021-12-07 Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients Wei, Cong Zhang, Xiaoting Liang, Dan Yang, Jilong Du, Jingwen Yue, Chunyan Deng, Lan Drug Des Devel Ther Original Research BACKGROUND: Graft-versus-host disease (GVHD) is a main complication following allogeneic hematopoietic stem cell transplantation and is a leading cause of non-relapse-related death. Unsatisfactory response to standard first-line therapy with glucocorticoids is a predictor of a poor prognosis in patients with GVHD. Ruxolitinib is a selective Janus kinases 1/2 inhibitor which has been shown to control acute (a) and chronic (c) GVHD while maintaining graft-versus-tumor effects. OBJECTIVE: This study aims to evaluate the efficacy and safety of ruxolitinib in the treatment of steroid-refractory GVHD (SR-GVHD) in a population of Chinese patients. METHODS: We report the results of 55 patients, including 23 patients with aGVHD and 32 patients with cGVHD, who were treated with ruxolitinib as salvage therapy between August, 2017 and December, 2020. RESULTS: In patients with aGVHD, the overall response rate (ORR) was 86.9%, and the 1-year overall survival (OS) was 82.6% (95% CI, 67.1–98.1%). The 1-year OS was significantly improved in responders than in non-responders (90.0% vs 33.3%, P=0.004). In patients with cGVHD, the ORR was 78.1%, and the 1-year OS was 81.3% (95% CI, 67.8–94.8%). There was no significant difference in the 1-year OS between responders and non-responders (84.0% vs 71.4%, P=0.327). Cytopenia, cytomegalovirus-reactivation and infections were common adverse events, particularly in patients with aGVHD. CONCLUSION: Our real-world data from Chinese patients further confirm that ruxolitinib is a safe and effective treatment for SR-GVHD. Dove 2021-11-30 /pmc/articles/PMC8646859/ /pubmed/34880598 http://dx.doi.org/10.2147/DDDT.S338752 Text en © 2021 Wei et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Wei, Cong Zhang, Xiaoting Liang, Dan Yang, Jilong Du, Jingwen Yue, Chunyan Deng, Lan Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients |
title | Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients |
title_full | Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients |
title_fullStr | Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients |
title_full_unstemmed | Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients |
title_short | Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients |
title_sort | ruxolitinib for treatment of steroid-refractory graft-versus-host disease: real-world data from chinese patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646859/ https://www.ncbi.nlm.nih.gov/pubmed/34880598 http://dx.doi.org/10.2147/DDDT.S338752 |
work_keys_str_mv | AT weicong ruxolitinibfortreatmentofsteroidrefractorygraftversushostdiseaserealworlddatafromchinesepatients AT zhangxiaoting ruxolitinibfortreatmentofsteroidrefractorygraftversushostdiseaserealworlddatafromchinesepatients AT liangdan ruxolitinibfortreatmentofsteroidrefractorygraftversushostdiseaserealworlddatafromchinesepatients AT yangjilong ruxolitinibfortreatmentofsteroidrefractorygraftversushostdiseaserealworlddatafromchinesepatients AT dujingwen ruxolitinibfortreatmentofsteroidrefractorygraftversushostdiseaserealworlddatafromchinesepatients AT yuechunyan ruxolitinibfortreatmentofsteroidrefractorygraftversushostdiseaserealworlddatafromchinesepatients AT denglan ruxolitinibfortreatmentofsteroidrefractorygraftversushostdiseaserealworlddatafromchinesepatients |